Tri Locum Partners LP
Tri Locum Partners LP reported 19 US-listed holdings worth $813.2 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Johnson & Johnson (13.3%), Vertex Pharmaceuticals Inc. (12.3%) and Eli Lilly & Co. (11.3%). Against the quarter before, it opened 5 positions, added to 8, trimmed 6 and sold out of 3.
The 14 largest of its 19 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +57.6% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 5
- Ascendis Pharma A/s ASND$69.0 million
- Enliven Therapeutics Inc. ELVN$44.0 million
- Revolution Medicines, Inc. RVMD$28.4 million
- Cytokinetics Inc. CYTK$16.5 million
- Beta Bionics Inc BBNX$7.7 million
Added to 8
- Axsome Therapeutics Inc. AXSM+157,192 shares · +253%
- Vertex Pharmaceuticals Inc. VRTX+72,477 shares · +56%
- Eli Lilly & Co. LLY+14,737 shares · +24%
- Jazz Pharmaceuticals plc JAZZ+63,057 shares · +40%
- argenx SE ARGX+9,961 shares · +31%
- Dexcom Inc. DXCM+122,321 shares · +18%
- Tarsus Pharmaceuticals Inc. TARS+75,752 shares · +30%
- Johnson & Johnson JNJ+10,442 shares · +3%
Trimmed 6
- Intuitive Surgical Inc. ISRG-105,267 shares · -69%
- Madrigal Pharmaceuticals Inc. MDGL-35,015 shares · -34%
- United Therapeutics Corp. UTHR-23,344 shares · -33%
- Definium Therapeutics Inc. DFTX-206,592 shares · -56%
- Teva Pharmaceutical Industries Ltd. TEVA-274,173 shares · -27%
- Dianthus Therapeutics Inc. DNTH-24,831 shares · -17%
Sold out of 3
- Thermo Fisher Scientific Inc. TMO$65.1 million last quarter
- Ascendis Pharma A/s ASND$58.4 million last quarter
- Nuvalent Inc. NUVL$31.6 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Johnson & Johnson JNJ | 424.9K | $107.9 million | 13.27% | +10.4K |
| Vertex Pharmaceuticals Inc. VRTX | 201.8K | $100.2 million | 12.33% | +72.5K |
| Eli Lilly & Co. LLY | 76.5K | $91.8 million | 11.29% | +14.7K |
| Ascendis Pharma A/s ASND | 258.7K | $69.0 million | 8.49% | new |
| Dexcom Inc. DXCM | 820.5K | $55.3 million | 6.80% | +122.3K |
| Axsome Therapeutics Inc. AXSM | 219.3K | $53.7 million | 6.60% | +157.2K |
| Jazz Pharmaceuticals plc JAZZ | 221.7K | $53.4 million | 6.57% | +63.1K |
| Enliven Therapeutics Inc. ELVN | 866.7K | $44.0 million | 5.41% | new |
| argenx SE ARGX | 41.6K | $38.6 million | 4.75% | +10.0K |
| Madrigal Pharmaceuticals Inc. MDGL | 68.3K | $36.7 million | 4.51% | -35.0K |
| Revolution Medicines, Inc. RVMD | 151.8K | $28.4 million | 3.50% | new |
| United Therapeutics Corp. UTHR | 47.0K | $25.5 million | 3.13% | -23.3K |
| Teva Pharmaceutical Industries Ltd. TEVA | 746.8K | $25.3 million | 3.11% | -274.2K |
| Tarsus Pharmaceuticals Inc. TARS | 328.3K | $20.7 million | 2.54% | +75.8K |
| Intuitive Surgical Inc. ISRG | 48.0K | $19.1 million | 2.35% | -105.3K |
| Cytokinetics Inc. CYTK | 194.0K | $16.5 million | 2.03% | new |
| Dianthus Therapeutics Inc. DNTH | 120.7K | $11.8 million | 1.45% | -24.8K |
| Beta Bionics Inc BBNX | 493.3K | $7.7 million | 0.95% | new |
| Definium Therapeutics Inc. DFTX | 163.0K | $7.7 million | 0.94% | -206.6K |